Press "Enter" to skip to content

Global Lung Cancer Therapeutics Market to Talk about Historical Development and Estimated Forecast

The study includes an analysis of market growth drivers, opportunities, challenges, restraints, trends, key strategies, market share, geographical analysis, and many more. Also, the study has focused on market size for various segments that are part of the industry. Analyzing the market on the basis of the competitive landscape provides a correct and real-time picture of the market matrix. The growth rate of the industry in coming years play an important role for investors, manufacturers, and stockholders to decide, whether it is the right time to invest in a particular market or not, this study also has focused on the growth rate of the market during the forecast period. For more info click here @ https://www.reportocean.com/industry-verticals/details?report_id=41354

Short Description

By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle east & Africa) Industry Trends and Forecast to 2026

Market Definition

In lung cancer, cell overgrowth occurs in the lungs and this will lead to less supply of oxygen in the blood stream. Lung cancer causes roughly around 1.6 million deaths each year (more deaths than colon, breast, prostate cancer combined). The lung cancer can be diagnosed by imaging tests, sputum cytology, tissue sample (biopsy). Lung cancer is generally of two types such as small cell lung cancer and non-small cell lung cancer. The non-small cell lung cancer accounts for almost 85% of the total lung cancer. Various treatment facilities are available for the treatment of lung cancer like immunotherapy, chemotherapy, radiation therapy, surgery.

Market Segmentation

> On the basis of cancer type, the market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumors, pulmonary neuroendocrine tumors, mediastinal tumors. The non-small cell lung cancer is further segmented into squamous cell carcinoma, pulmonary adenocarcinoma, adenosquamous carcinoma (ASC), large cell carcinoma, sarcomatoid carcinoma, undifferentiated non-small cell lung cancer, salivary gland-type lung carcinoma. The chest wall tumors segment is further sub divided into primary tumors, metastatic tumors, sarcomas. The pulmonary neuroendocrine tumors are further segmented into carcinoid tumors, large cell neuroendocrine lungs carcinoma and small-cell lung cancer. The mediastinal tumors are further segmented into germ cell tumors, lymphomas, thymomas. The salivary gland-type lung carcinoma sub-segment is further divided into adenoid cystic carcinoma, mucoepidermoid carcinoma, acinic cell carcinoma, epithelial-myoepithelial carcinoma, granular cell lung tumours. The carcinoid tumors sub-segment is further divided into typical carcinoid tumors, atypical carcinoid tumors. The small-cell lung cancer sub-segment is further divided into small cell carcinoma, combined small cell carcinoma.

> On the basis of molecule type, the market is segmented into small molecules, biologics.

> On the drug class, the market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors, others.

> On the basis of treatment type, the market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs. The radiation therapy segment is further divided into external beam, brachytherapy (internal or implant radiation therapy), systemic, stereotactic body radiation therapy (SBRT)/stereotactic ablative radiotherapy (SABR), stereotactic radiosurgery (SRS). The chemotherapy segment is further divided into cisplatin, paclitaxel (taxol), docetaxel (taxotere), gemcitabine (gemzar), alimta, vinorelbine (navelbine), durvalumab (imfinzi) and others. The targeted therapy segment is further divided into epidermal growth factor receptor (EGFR) inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, anti-angiogenesis therapy, monoclonal antibodies, others. The immunotherapy segment is further divided into atezolizumab (tecentriq), durvalumab (imfinzi), nivolumab (opdivo), pembrolizumab (keytruda) others.

> On the basis of therapy type, the market is segmented into single drug therapy, combination therapy.

> On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare, others.

> On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online and others.

Market Players

Some of the prominent players operating in this market are:

> Takeda Pharmaceutical Company Limited

> ONO PHARMACEUTICAL CO., LTD.

> F. Hoffmann-La Roche Ltd

> Novartis AG

> Eli Lilly and Company.

> AstraZeneca

> Boehringer Ingelheim International GmbH

> Merck & Co., Inc.

> CELGENE CORPORATION

> AMGEN INC.

> Sanofi

> Johnson & Johnson Services, Inc.

> Pfizer Inc.

> Sun Pharmaceutical Industries Ltd.

> Dr. Reddy’s Laboratories Ltd.

> ALLERGAN

> Teva Pharmaceutical Industries Ltd.

> Bristol-Myers Squibb Company

> GlaxoSmithKline plc.

> Astellas Pharma Inc.

> Sumitomo Dainippon Pharma Co., Ltd

> Others

Continue…

View Full Report Detail and Table of Content at https://www.reportocean.com/industry-verticals/details?report_id=41354

Request Free Sample Report at https://www.reportocean.com/industry-verticals/sample-request?report_id=41354

TABLE OF CONTENTS

1 INTRODUCTION 44

1.1 OBJECTIVES OF THE STUDY 44

1.2 MARKET DEFINITION 44

1.3 OVERVIEW OF GLOBAL LUNG CANCER THERAPEUTICS MARKET 44

1.4 CURRENCY AND PRICING 46

1.5 LIMITATIONS 46

1.6 MARKETS COVERED 47

2 MARKET SEGMENTATION 51

2.1 MARKETS COVERED 51

2.2 GEOGRAPHICAL SCOPE 52

2.3 YEARS CONSIDERED FOR THE STUDY 53

2.4 CURRENCY AND PRICING 53

2.5 RESEARCH METHODOLOGY 54

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 57

2.7 DBMR MARKET POSITION GRID 58

2.8 DBMR MARKET CHALLENGE MATRIX 60

2.9 DBMR VENDOR SHARE ANALYSIS 61

2.10 MULTIVARIATE MODELLING 61

2.11 PRODUCT TIME LINE 62

2.12 SECONDARY SOURCES 63

2.13 ASSUMPTIONS 63

3 MARKET OVERVIEW 64

3.1 DRIVERS 66

3.1.1 INCREASING CASES OF LUNG CANCER 66

3.1.2 GROWING NUMBER OF SMOKERS 67

3.1.3 GOVERNMENT / ORGANIZATIONS FUNDING FOR THE R&D OF NEW DRUGS 68

3.1.4 INCREASING AWARENESS 68

3.1.5 STRATEGIC INITIATIVES OF THE COMPANIES 69

3.2 RESTRAINS 70

3.2.1 PRICING PRESSURE 70

3.2.2 HIGH COST 71

3.3 OPPORTUNITIES 72

3.3.1 APPROVALS AND PRODUCT PIPEPLINE 72

3.3.2 HEALTH TOURISM 73

3.3.3 NEW PRODUCT LAUNCHES 74

?

3.4 CHALLENGES 75

3.4.1 SIDE EFFECTS 75

3.4.2 LACK OF NUMBER OF ONCOLOGISTS 76

3.4.3 UNMET MEDICAL NEEDS 76

4 EXECUTIVE SUMMARY 77

5 PREMIUM INSIGHTS 81

6 EPIDEMIOLOGY OF LUNG CANCER 83

7 REGULATORY PROCEDURE 86

8 PIPELINE DRUGS 88

9 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE 92

9.1 OVERVIEW 93

9.2 NON-SMALL CELL LUNG CANCER 94

9.2.1 SQUAMOUS CELL CARCINOMA 95

9.2.2 PULMONARY ADENOCARCINOMA 96

9.2.3 ADENOSQUAMOUS CARCINOMA (ASC) 96

9.2.4 LARGE CELL CARCINOMA 96

9.2.5 SARCOMATOID CARCINOMA 97

9.2.6 UNDIFFERENTIATED NON-SMALL CELL LUNG CANCER 97

9.2.7 SALIVARY GLAND-TYPE LUNG CARCINOMA 97

9.2.7.1 ADENOID CYSTIC CARCINOMA 98

9.2.7.2 MUCOEPIDERMOID CARCINOMA 98

9.2.7.3 ACINIC CELL CARCINOMA 98

9.2.7.4 EPITHELIAL-MYOEPITHELIAL CARCINOMA 98

9.2.7.5 GRANULAR CELL LUNG TUMORS 98

9.3 METASTATIC LUNG CANCER 99

9.4 MESOTHELIOMA 100

9.5 CHEST WALL TUMORS 101

9.5.1 PRIMARY TUMORS 101

9.5.2 METASTATIC TUMORS 101

9.5.3 SARCOMAS 102

9.6 PULMONARY NEUROENDOCRINE TUMORS 102

9.6.1 CARCINOID TUMORS 103

9.6.1.1 TYPICAL CARCINOID TUMORS 103

9.6.1.2 ATYPICAL CARCINOID TUMORS 103

9.6.2 LARGE CELL NEUROENDOCRINE LUNGS CARCINOMA 103

9.6.3 SMALL-CELL LUNG CANCER 104

9.6.3.1 SMALL CELL CARCINOMA 104

9.6.3.2 COMBINED SMALL CELL CARCINOMA 104

9.7 MEDIASTINAL TUMORS 105

9.7.1 GERM CELL TUMORS 106

9.7.2 LYMPHOMAS 106

9.7.3 THYMOMAS 106

10 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE 107

10.1 OVERVIEW 108

10.2 SMALL MOLECULE 110

10.3 BILOGICS 111

11 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS 112

11.1 OVERVIEW 113

11.2 ALKYLATING AGENTS 114

11.3 ANTIMETABOLITES 115

11.4 MITOTIC INHIBITORS 116

11.5 MULTIKINASE INHIBITORS 117

11.6 EGFR INHIBITORS 118

11.7 OTHERS 118

12 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE 119

12.1 OVERVIEW 120

12.2 RADIATION THERAPY 121

12.2.1 EXTERNAL BEAM 122

12.2.2 BRACHYTHERAPY (INTERNAL OR IMPLANT RADIATION THERAPY) 122

12.2.3 STEREOTACTIC BODY RADIATION THERAPY (SBRT) / STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) 122

12.2.4 STEREOTACTIC RADIOSURGERY (SRS) 122

12.3 CHEMOTHERAPY 123

12.3.1 CISPLATIN 124

12.3.2 PACLITAXEL (TAXOL) 124

12.3.3 VINORELBINE (NAVELBINE) 124

12.3.4 DOCETAXEL (TAXOTERE) 124

12.3.5 ALIMTA 124

12.3.6 GEMCITABINE (GEMZAR) 124

12.3.7 DURVALUMAB (IMFINZI) 124

12.3.8 OTHERS 124

12.4 TARGETED THERAPY 125

12.4.1 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS 126

12.4.2 ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS 126

12.4.3 ANTI-ANGIOGENESIS THERAPY 126

12.4.4 MONOCLONAL ANTIBODIES 126

12.4.5 OTHERS 126

12.5 IMMUNOTHERAPY 127

12.5.1 ATEZOLIZUMAB (TECENTRIQ) 128

12.5.2 DURVALUMAB (IMFINZI) 128

12.5.3 NIVOLUMAB (OPDIVO) 128

12.5.4 PEMBROLIZUMAB (KEYTRUDA) 128

12.6 OTHERS 128

13 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE 129

13.1 OVERVIEW 130

13.2 SINGLE DRUG THERAPY 131

13.3 COMBINATION THERAPY 132

14 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY END USER 133

14.1 OVERVIEW 134

14.2 HOSPITALS 135

14.3 SPECIALTY CLINICS 136

14.4 HOMECARE 137

14.5 OTHERS 138

15 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 139

15.1 OVERVIEW 140

15.2 HOSPITAL PHARMACY 141

15.3 RETAIL PHARMACY 142

15.4 ONLINE 142

15.5 OTHERS 143

16 GLOBAL LUNG CANCER THERAPEUTICS MARKET, BY GEOGRAPHY 144

16.1 OVERVIEW 145

16.2 NORTH AMERICA 150

16.2.1 U.S. 159

16.2.2 CANADA 165

16.2.3 MEXICO 171

16.3 EUROPE 177

16.3.1 GERMANY 186

16.3.2 FRANCE 192

16.3.3 U.K. 198

16.3.4 ITALY 204

16.3.5 SPAIN 210

16.3.6 SWITZERLAND 216

16.3.7 NETHERLANDS 222

16.3.8 BELGIUM 228

16.3.9 RUSSIA 234

16.3.10 TURKEY 240

16.3.11 REST OF EUROPE 246

16.4 ASIA-PACIFIC 247

16.4.1 JAPAN 256

16.4.2 CHINA 262

16.4.3 INDIA 268

16.4.4 AUSTRALIA 274

16.4.5 SOUTH KOREA 280

16.4.6 INDONESIA 286

16.4.7 THAILAND 292

16.4.8 MALAYSIA 298

16.4.9 SINGAPORE 304

16.4.10 PHILIPPINES 310

16.4.11 REST OF ASIA-PACIFIC 316

16.5 SOUTH AMERICA 317

16.5.1 BRAZIL 326

16.5.2 REST OF SOUTH AMERICA 332

16.6 MIDDLE EAST AND AFRICA 333

16.6.1 SOUTH AFRICA 342

16.6.2 REST OF MIDDLE EAST AND AFRICA 348

17 GLOBAL LUNG CANCER THERAPEUTICS MARKET, COMPANY LANDSCAPE 349

17.1 COMPANY SHARE ANALYSIS: GLOBAL 349

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 350

17.3 COMPANY SHARE ANALYSIS: EUROPE 351

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 352

18 COMPANY PROFILES 353

18.1 F. HOFFMANN-LA ROCHE LTD 353

18.1.1 COMPANY SNAPSHOT 353

18.1.2 REVENUE ANALYSIS 353

18.1.3 GEOGRAPHICAL PRESENCE 354

18.1.4 COMPANY SHARE ANALYSIS 354

18.1.5 PRODUCT PORTFOLIO 355

18.1.6 RECENT DEVELOPMENTS 355

18.2 MERCK & CO., INC. 356

18.2.1 COMPANY OVERVIEW 356

18.2.2 REVENUE ANALYSIS 356

18.2.3 GEOGRAPHICAL PRESENCE 357

18.2.4 COMPANY SHARE ANALYSIS 357

18.2.5 PRODUCT PORTFOLIO 358

18.2.6 RECENT DEVELOPMENTS 358

18.3 BRISTOL-MYERS SQUIBB COMPANY 359

18.3.1 COMPANY OVERVIEW 359

18.3.2 REVENUE ANALYSIS 359

18.3.3 GEOGRAPHICAL PRESENCE 360

18.3.4 COMPANY SHARE ANALYSIS 360

18.3.5 PRODUCT PORTFOLIO 361

18.3.6 RECENT DEVELOPMENTS 361

18.4 ASTRAZENECA 362

18.4.1 COMPANY SNAPSHOT 362

18.4.2 REVENUE ANALYSIS 362

18.4.3 GEOGRAPHICAL PRESENCE 363

18.4.4 COMPANY SHARE ANALYSIS 363

18.4.5 PRODUCT PORTFOLIO 364

18.4.6 RECENT DEVELOPMENTS 364

18.5 ELI LILLY AND COMPANY 365

18.5.1 COMPANY SNAPSHOT 365

18.5.2 REVENUE ANALYSIS 365

18.5.3 GEOGRAPHICAL PRESENCE 366

18.5.4 COMPANY SHARE ANALYSIS 366

18.5.5 PRODUCT PORTFOLIO 367

18.5.6 RECENT DEVELOPMENTS 367

18.6 ALLERGAN 368

18.6.1 COMPANY OVERVIEW 368

18.6.2 REVENUE ANALYSIS 368

18.6.3 GEOGRAPHICAL PRESENCE 369

18.6.4 PRODUCT PORTFOLIO 369

18.6.5 RECENT DEVELOPMENTS 370

18.7 AMGEN INC. 371

18.7.1 COMPANY OVERVIEW 371

18.7.2 REVENUE ANALYSIS 371

18.7.3 GEOGRAPHICAL PRESENCE 372

18.7.4 PRODUCT PORTFOLIO 372

18.7.5 RECENT DEVELOPMENTS 373

18.8 ASTELLAS PHARMA INC. 374

18.8.1 COMPANY OVERVIEW 374

18.8.2 REVENUE ANALYSIS 374

18.8.3 GEOGRAPHICAL PRESENCE 375

18.8.4 PRODUCT PORTFOLIO 375

18.8.5 RECENT DEVELOPMENTS 376

18.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 377

18.9.1 COMPANY OVERVIEW 377

18.9.2 REVENUE ANALYSIS 377

18.9.3 GEOGRAPHICAL PRESENCE 378

18.9.4 PRODUCT PORTFOLIO 378

18.9.5 RECENT DEVELOPMENTS 379

18.10 CELGENE CORPORATION 380

18.10.1 COMPANY OVERVIEW 380

18.10.2 REVENUE ANALYSIS 380

18.10.3 GEOGRAPHICAL PRESENCE 381

18.10.4 PRODUCT PORTFOLIO 381

18.10.5 RECENT DEVELOPMENTS 381

18.11 DR. REDDY’S LABORATORIES LTD. 382

18.11.1 COMPANY SNAPSHOT 382

18.11.2 REVENUE ANALYSIS 382

18.11.3 GEOGRAPHICAL PRESENCE 383

18.11.4 PRODUCT PORTFOLIO 383

18.11.5 RECENT DEVELOPMENTS 384

18.12 GLAXOSMITHKLINE PLC. 385

18.12.1 COMPANY OVERVIEW 385

18.12.2 REVENUE ANALYSIS 385

18.12.3 GEOGRAPHICAL PRESENCE 386

18.12.4 PRODUCT PORTFOLIO 386

18.12.5 RECENT DEVELOPMENTS 387

18.13 JOHNSON & JOHNSON SERVICES, INC. 388

18.13.1 COMPANY SNAPSHOT 388

18.13.2 REVENUE ANALYSIS 388

18.13.3 GEOGRAPHICAL PRESENCE 389

18.13.4 PRODUCT PORTFOLIO 389

18.13.5 RECENT DEVELOPMENTS 390

18.14 NOVARTIS AG 391

18.14.1 COMPANY SNAPSHOT 391

18.14.2 REVENUE ANALYSIS 391

18.14.3 GEOGRAPHICAL PRESENCE 392

18.14.4 PRODUCT PORTFOLIO 392

18.14.5 RECENT DEVELOPMENT 393

18.15 ONO PHARMACEUTICAL CO., LTD. 394

18.15.1 COMPANY OVERVIEW 394

18.15.2 REVENUE ANALYSIS 394

18.15.3 GEOGRAPHICAL PRESENCE 395

18.15.4 PRODUCT PORTFOLIO 395

18.15.5 RECENT DEVELOPMENTS 396

18.16 PFIZER INC. 397

18.16.1 COMPANY SNAPSHOT 397

18.16.2 RECENT FINANCIALS 397

18.16.3 GEOGRAPHICAL PRESENCE 398

18.16.4 PRODUCT PORTFOLIO 398

18.16.5 RECENT DEVELOPMENTS 399

18.17 SANOFI 401

18.17.1 COMPANY OVERVIEW 401

18.17.2 REVENUE ANALYSIS 401

18.17.3 GEOGRAPHICAL PRESENCE 402

18.17.4 PRODUCT PORTFOLIO 402

18.17.5 RECENT DEVELOPMENTS 403

18.18 SUMITOMO DAINIPPON PHARMA CO., LTD. 404

18.18.1 COMPANY OVERVIEW 404

18.18.2 REVENUE ANALYSIS 404

18.18.3 GEOGRAPHICAL PRESENCE 405

18.18.4 PRODUCT PORTFOLIO 405

18.18.5 RECENT DEVELOPMENTS 405

18.19 SUN PHARMACEUTICAL INDUSTRIES LTD. 407

18.19.1 COMPANY SNAPSHOT 407

18.19.2 REVENUE ANALYSIS 407

18.19.3 GEOGRAPHICAL PRESENCE 408

18.19.4 PRODUCT PORTFOLIO 408

18.19.5 RECENT DEVELOPMENTS 409

18.20 TAKEDA PHARMACEUTICAL COMPANY LIMITED 410

18.20.1 COMPANY OVERVIEW 410

18.20.2 REVENUE ANALYSIS 410

18.20.3 GEOGRAPHICAL PRESENCE 411

18.20.4 PRODUCT PORTFOLIO 411

18.20.5 RECENT DEVELOPMENTS 412

18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. 413

18.21.1 COMPANY OVERVIEW 413

18.21.2 REVENUE ANALYSIS 413

18.21.3 GEOGRAPHICAL PRESENCE 414

18.21.4 PRODUCT PORTFOLIO 414

18.21.5 RECENT DEVELOPMENTS 414

19 QUESTIONNAIRE 415

20 RELATED REPORTS 422

?

Request Free Sample Report at https://www.reportocean.com/industry-verticals/sample-request?report_id=41354

Note: The report historic years and forecast period can be customized on the request. Moreover, the scope of a published report can be modified as per the requirement, specific geography or ‘country-based’ analysis can be provided as a part of customization

Follow us on:

Facebook:          https://www.facebook.com/reportocean

Twitter:              https://twitter.com/reportocean

LinkedIn:            https://in.linkedin.com/company/reportocean

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)
Contact Person: Sandeep Singh
Email: sales@reportocean.com

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *